Melphalan: Old and new uses of a still master drug for multiple myeloma

Pellegrino Musto, Fiorella D'Auria

Research output: Contribution to journalArticlepeer-review


The treatment of multiple myeloma has seen significant changes from the initial use of melphalan to the introduction of stem cell transplantation and, most recently, to the era of novel targeted agents. Melphalan still remains as a reference drug for combination regimens, including emerging newer therapeutic options, either used at a standard dose for initial or salvage treatments in patients who are not eligible for more intensive therapies, or in conjunction with new molecules within high-dose chemotherapy programs. In this review, the authors analyze old and novel regimens, including melphalan for the treatment of newly diagnosed or relapsed/resistant patients with multiple myeloma in the clinical settings of standard chemotherapy, as well as autologous or allogeneic stem cell transplantation.

Original languageEnglish
Pages (from-to)1467-1487
Number of pages21
JournalExpert Opinion on Investigational Drugs
Issue number9
Publication statusPublished - Sep 2007


  • Bortezomib
  • Lenalidomide
  • Melphalan
  • Multiple myeloma
  • Stem cell transplantation
  • Thalidomide

ASJC Scopus subject areas

  • Pharmacology


Dive into the research topics of 'Melphalan: Old and new uses of a still master drug for multiple myeloma'. Together they form a unique fingerprint.

Cite this